<div class="white-sheet">
    <div class="content-slide">

<!-- Secondary scene 1 -->
    <div class="content secondary-scene">
        <!--<h1>Content</h1>-->
        

                <div class="title-bar red"></div>

                <div class="wrapper slide-2-6-1">

                    <div class="vertical-nav">
                        <ul class="two">
                            <li class="active"></li>
                            <li></li>
                        </ul>
                    </div>

                    <div class="popups" style="position:absolute">
                        <div data-effect="fade" data-duration="1000" data-target="references1-overlay" data-width="600" data-height="490" class="references-button show-overlay"></div>
                        <div data-effect="fade" data-duration="1000" data-target="information-overlay" data-width="600" data-height="490" class="information-button show-overlay"></div> 
                    </div>

                    <div class="slide-title red two-line">
                        Acquired aplastic anaemia treatment: <br />for whom and when?<sup>1-4</sup>
                    </div>


                    <div class="content-container">
                
                        <img src="media/images/slide_2-6-1/picture1.png" class="center-img" alt="">

                        <p class="small-print">AA, aplastic anaemia; SAA, severe aplastic anaemia</p>

                    </div>

                </div>

                <div class="information-overlay overlay">

                    <header>Acquired aplastic anaemia treatment: for whom and when?</header>
                        
                    <ul>
                        <li><span>Non-severe aplastic anaemia:</span>
                            <ul>
                                <li><span>Variable clinical course, but seldom life-threatening<sup>1</sup></span></li>
                                <li><span>Patients may have moderate cytopenia but are asymptomatic<sup>2</sup></span></li>
                                <li><span>Supportive care with anabolic/low-dose steroids or CsA can be offered<sup>2</sup></span></li>
                            </ul>
                        </li>
                        <li><span>These patients may eventually demonstrate declining peripheral blood counts over time (months)<sup>2</sup></span></li>
                        <li><span>Severe aplastic anaemia almost always requires treatment<sup>3</sup></span></li>
                        <li><span>Supportive measures include:<sup>1</sup></span>
                            <ul>
                                <li><span>Transfusions of blood products (e.g. red blood cells and platelets) to:</span>
                                    <ul>
                                        <li><span>Correct or avoid anaemia-associated cardiopulmonary complications</span></li>
                                        <li><span>Prevent spontaneous bleeding</span></li>
                                        <li><span>Support recovery in the event of infection</span></li>
                                    </ul>
                                </li>
                                <li><span>Prophylactic antibiotics</span>
                                    <ul>
                                        <li><span>Fungal and bacterial infections are a major cause of death in patients with severe aplastic anaemia</span></li>
                                    </ul>
                                </li>
                                <li><span>Treatment with growth factors (e.g. G-CSF) to stimulate neutrophil response</span></li>
                            </ul>
                        </li>
                        <li><span>Definitive treatment: haematopoiesis can be restored in severe aplastic anaemia after HSCT<sup>3</sup></span></li>
                    </ul>

                </div>


                <div class="references1-overlay overlay">

                    <header>References</header>
                        
                    <ol>
                        <li class="navigateHref" data-navtarget="media/documents/module2/DeZernA-2011-ExpertRevHematol-v4p221.pdf"><span>DeZern AE & Brodsky RA. <i>Exp Rev Hematol</i> 2011;4:221</span></li>
                        <li class="navigateHref" data-navtarget="media/documents/module2/BacigalupoA-2009-HematolOncolClinNAm-v23p159.pdf"><span>Bacigalupo A & Passweg J <i>et al. Haematol Oncol Clin N Am</i> 2009;23:159</span></li>
                        <li class="navigateHref" data-navtarget="media/documents/module2/ScheinbergP-2012-Blood-v120p1185.pdf"><span>Scheinberg P & Young NS. <i>Blood</i> 2012;120:1185</span></li>
                        <li class="navigateHref" data-navtarget="media/documents/module2/YoungNS-2010-BiolBloodMrrowTransplant-v16pS119.pdf"><span>Young NS <i>et al. Biol Blood Marrow Transplant</i> 2010;16:S119 </span></li>
                        <li style="list-style:none"><span>Figure adapted from references 1-4</span></li>
                    </ol>

                </div>


          
    </div>
    <!-- End of secondary scene 1 -->
    <!-- Secondary scene 2 (Static Content) -->
    <div class="content secondary-scene">
         

                <div class="title-bar blue"></div>

                <div class="wrapper slide-2-6-1a">

                    <div class="vertical-nav">
                        <ul class="two">
                            <li></li>
                            <li class="active"></li>
                        </ul>
                    </div>

                    <div class="popups" style="position:absolute">
                        <div data-effect="fade" data-duration="1000" data-target="references2-overlay" data-width="600" data-height="490" class="references-button show-overlay"></div>        
                    </div>

                    <div class="slide-title blue two-line">
                        Supportive care considerations in <br />severe aplastic anaemia
                    </div>


                    <div class="content-container">
                
                        <ul>
                            <li><span>The type of supportive care required for an individual depends on the severity of their symptoms and pancytopenia<sup>1</sup></span></li>
                            <li><span>Evidence supporting the use of human growth factors to sustain blood counts in severe aplastic anaemia is mixed<sup>1</sup></span>
                                <ul>
                                    <li><span>G-CSF may be used to stimulate a neutrophil response in the presence of severe infection and as an adjunct to immunosuppressive therapy (IST)<sup>1</sup></span>
                                        <ul>
                                            <li><span>However, data suggest that G-CSF may not modify overall haematological response or survival<sup>1</sup></span></li>
                                        </ul>
                                    </li>
                                    <li><span>A potential concern is that the use of recombinant human erythropoietin (rHuEPO) may increase the risk of the patient developing anti-rHuEPO antibodies<sup>2,3</sup></span>
                                        <ul>
                                            <li><span>This may result in a sudden worsening of anaemia due to red cell aplasia<sup>2,3</sup></span></li>
                                        </ul>
                                    </li>
                                    <li><span>IST is the first-line therapy for severe aplastic anaemia patients &gt;40 years or &lt;40 years of age who lack a human leukocyte antigen (HLA)-compatible sibling<sup>4</sup></span></li>
                                </ul>
                            </li>
                            <li><span>Repeated transfusion of blood products can lead to iron overload, causing significant damage to internal organs and increasing mortality risk<sup>5</sup></span>
                                <ul>
                                    <li><span>Current evidence suggests that daily chelation with deferasirox may be effective in reducing serum ferritin and liver transaminase levels, and that it is a well-tolerated therapy<sup>5</sup></span></li>
                                </ul>
                            </li>
                        </ul>       

                    </div>

                </div>


                <div class="references2-overlay overlay">

                    <header>References</header>
                        
                    <ol>
                        <li class="navigateHref" data-navtarget="media/documents/module2/DeZernA-2011-ExpertRevHematol-v4p221.pdf"><span>DeZern AE & Brodsky RA. <i>Exp Rev Hematol</i> 2011;4:221</span></li>
                        <li class="navigateHref" data-navtarget="media/documents/module2/MarshJ-2009-BrJHaematol-v147p43.pdf"><span>Marsh JCW <i>et al. Br J Haematol</i> 2009;147:43</span></li>
                        <li class="navigateHref" data-navtarget="media/documents/module2/CasadevallN-2002-NEJM-v346p469.pdf"><span>Casadevall N <i>et al. N Engl J Med</i> 2002;346:469</span></li>
                        <li class="navigateHref" data-navtarget="media/documents/module2/YoungNS-2010-BiolBloodMrrowTransplant-v16pS119.pdf"><span>Young NS <i>et al. Biol Blood Marrow</i> Transplant 2010;16:S119</span></li>
                        <li class="navigateHref" data-navtarget="media/documents/module2/LeeJW-2010-Blood-v116p2448.pdf"><span>Lee JW <i>et al. Blood</i> 2010;116:2448</span></li>
                    </ol>

                </div>

          
    </div>
    <!-- End of secondary scene 2 -->
    </div>
 </div>